PharmaCorp Rx Inc.
PCRX.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4,557.93% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4,557.93% | -- | -- | -- | -- |
| Cost of Revenue | 4,178.50% | -- | -- | -- | -- |
| Gross Profit | 5,299.58% | -- | -- | -- | -- |
| SG&A Expenses | 333.49% | 524.68% | 492.47% | 614.97% | 456.33% |
| Depreciation & Amortization | 2,700.61% | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 862.50% | 1,419.75% | 1,148.44% | 883.72% | 549.41% |
| Operating Income | 27.43% | -64.59% | -174.08% | -500.94% | -423.37% |
| Income Before Tax | 77.00% | -5.12% | -147.41% | -664.99% | -720.24% |
| Income Tax Expenses | 56,800.00% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 63.14% | -4.91% | -125.56% | -665.25% | -720.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1,741.67% | -- | -- | -- | -- |
| Net Income | 65.58% | -0.96% | -118.14% | -665.20% | -721.34% |
| EBIT | 27.43% | -64.59% | -174.08% | -500.94% | -423.37% |
| EBITDA | 42.61% | -- | -- | -- | -- |
| EPS Basic | 90.26% | 62.62% | 1.17% | -211.70% | -444.90% |
| Normalized Basic EPS | 94.61% | 63.43% | -0.93% | -210.17% | -438.71% |
| EPS Diluted | 90.26% | 62.62% | 1.17% | -211.70% | -444.90% |
| Normalized Diluted EPS | 94.61% | 63.43% | -0.93% | -210.17% | -438.71% |
| Average Basic Shares Outstanding | 297.75% | 395.15% | 278.38% | 159.24% | 44.73% |
| Average Diluted Shares Outstanding | 297.75% | 395.15% | 278.38% | 159.24% | 44.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |